Levi & Korsinsky Notifies Investors of a Pending Investigation Into Securities Claims Involving Ionis Pharmaceuticals (IONS)
GlobeNewsWire
Published: Jul 14, 2026, 02:20 PM
Sentiment Analysis
Ionis Pharmaceuticals (NASDAQ: IONS) shares dropped more than 20% by midday trading on July 9, 2026, after the Company disclosed that its late-stage CARDIO-TTRansform trial failed to meet its primary endpoint.
The CARDIO-TTRansform program, partnered with AstraZeneca, was studied in patients with transthyretin-mediated amyloid cardiomyopathy. The primary endpoint measured the reduction of combined cardiovascular death and recurrent events. On July 9, 2026, the Company announced the trial did not achieve that endpoint, and shares fell sharply in pre-market trading.
The investigation concerns whether prior statements to investors regarding the CARDIO-TTRansform program were accurate and complete.
Source: GlobeNewsWire
This content is not intended as investment advice or a recommendation. Any opinions expressed are solely the personal views of each article.